Get the Stockscreener App
319.82
1.11%
-3.58
After Hours:
319.82
Insulet Corporation stock is traded at $319.82, with a volume of 677.04K.
It is down -1.11% in the last 24 hours and up +2.03% over the past month.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.
See More
Previous Close:
$323.40
Open:
$326.35
24h Volume:
677.04K
Relative Volume:
1.09
Market Cap:
$22.51B
Revenue:
$2.36B
Net Income/Loss:
$236.10M
P/E Ratio:
97.33
EPS:
3.286
Net Cash Flow:
$382.50M
1W Performance:
+2.18%
1M Performance:
+2.03%
6M Performance:
+21.00%
1Y Performance:
+30.55%
1-Day Range:
$316.86
$332.95
1-Week Range:
$290.16
$335.00
52-Week Range:
$230.05
$353.50
Insulet Corporation Stock (PODD) Company Profile
Name
Insulet Corporation
Sector
Industry
Phone
978-600-7000
Address
100 NAGOG PARK, ACTON, MA
Compare PODD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PODD
Insulet Corporation
|
319.82 | 22.76B | 2.36B | 236.10M | 382.50M | 3.286 |
|
ABT
Abbott Laboratories
|
126.36 | 217.27B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
100.02 | 146.84B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
356.03 | 135.31B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
92.20 | 115.51B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
83.39 | 47.84B | 5.88B | 1.34B | 799.60M | 2.3489 |
Insulet Corporation Stock (PODD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-21-25 | Resumed | Stifel | Buy |
| Sep-08-25 | Resumed | Oppenheimer | Outperform |
| Jun-16-25 | Initiated | Truist | Buy |
| May-30-25 | Initiated | Goldman | Buy |
| May-13-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Apr-29-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Mar-06-25 | Initiated | RBC Capital Mkts | Outperform |
| Nov-06-24 | Initiated | Bernstein | Outperform |
| May-30-24 | Initiated | Redburn Atlantic | Buy |
| May-07-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-21-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-04-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-02-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-21-23 | Upgrade | Citigroup | Neutral → Buy |
| Aug-21-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-26-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-04-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-18-22 | Initiated | Barclays | Equal Weight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-11-22 | Downgrade | Citigroup | Buy → Neutral |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Feb-03-22 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-02-22 | Upgrade | UBS | Neutral → Buy |
| Jan-31-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-01-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-19-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Jan-29-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Jul-28-20 | Initiated | Wells Fargo | Overweight |
| Apr-24-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-03-20 | Initiated | BofA/Merrill | Neutral |
| Mar-31-20 | Downgrade | Berenberg | Buy → Hold |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Dec-10-19 | Initiated | CFRA | Sell |
| Oct-23-19 | Initiated | Stifel | Hold |
| Oct-18-19 | Downgrade | Canaccord Genuity | Buy → Hold |
| Oct-14-19 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-04-19 | Downgrade | UBS | Buy → Neutral |
| Oct-03-19 | Downgrade | Guggenheim | Buy → Neutral |
| Aug-06-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-10-19 | Downgrade | Northland Capital | Outperform → Market Perform |
| May-06-19 | Upgrade | BTIG Research | Neutral → Buy |
| Apr-20-18 | Initiated | Berenberg | Buy |
| Feb-22-18 | Reiterated | Barclays | Overweight |
| Jan-08-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Nov-03-17 | Upgrade | Canaccord Genuity | Hold → Buy |
| Sep-15-17 | Initiated | Barclays | Overweight |
View All
Insulet Corporation Stock (PODD) Latest News
Multi asset correlation models including Insulet CorporationPrice Action & Low Drawdown Momentum Ideas - newser.com
Will Insulet Corporation rebound enough to break evenStop Loss & Accurate Entry/Exit Alerts - newser.com
What machine learning models say about Insulet CorporationExit Point & Weekly Watchlist for Hot Stocks - newser.com
Insulet price target raised to $390 from $365 at Truist - TipRanks
Insulet Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions - simplywall.st
Results: Insulet Corporation Exceeded Expectations And The Consensus Has Updated Its Estimates - 富途牛牛
Will Insulet Corporation stock recover after recent dropTrade Performance Summary & Community Verified Watchlist Alerts - newser.com
Best data tools to analyze Insulet Corporation stockM&A Rumor & Pattern Based Trade Signal System - newser.com
Will Insulet Corporation outperform the marketMarket Movers & Fast Gain Swing Trade Alerts - newser.com
Sector ETF performance correlation with Insulet CorporationMarket Sentiment Review & Safe Capital Allocation Plans - newser.com
Canaccord Genuity Maintains Insulet (PODD) Buy Recommendation - Nasdaq
Insulet (PODD): Evaluating Valuation After Q3 2025 Results, Upgraded Guidance, and Omnipod Expansion - Yahoo Finance Australia
Understanding Momentum Shifts in (PODD) - news.stocktradersdaily.com
RBC Capital Maintains Insulet (PODD) Outperform Recommendation - Nasdaq
Insulet Corp. stock outperforms competitors despite losses on the day - MarketWatch
Wells Fargo Raises Price Target for Insulet (PODD) to $360 | POD - GuruFocus
Barclays Raises Price Target for Insulet (PODD) to $316 | PODD S - GuruFocus
PODD: RBC Capital Raises Price Target for Insulet to $370, Maint - GuruFocus
UBS Maintains Neutral Rating on PODD, Raises Price Target | PODD Stock News - GuruFocus
3 Reasons Why Growth Investors Shouldn't Overlook Insulet (PODD) - sharewise.com
Bernstein Adjusts Insulet Price Target to $410 From $400 - MarketScreener
Did Insulet's (PODD) Upbeat Quarter and Raised Outlook Just Shift Its Investment Narrative? - Yahoo Finance
Truist Securities Reiterates 'Buy' Rating, Raises Target for Ins - GuruFocus
RBC Adjusts Price Target on Insulet to $370 From $365, Maintains Outperform Rating - MarketScreener
UBS Adjusts Price Target on Insulet to $355 From $320, Maintains Neutral Rating - MarketScreener
Why Insulet Corporation (GOV) stock stays resilientBear Alert & Low Risk High Win Rate Stock Picks - newser.com
Is Insulet Corporation stock poised for growthQuarterly Trade Report & Trade Opportunity Analysis Reports - newser.com
Insulet Corp (PODD)'s Winning Formula: Financial Metrics and Com - GuruFocus
Insulet Corporation (NASDAQ:PODD) Q3 2025 Earnings Call Transcript - Insider Monkey
Insulet price target raised to $360 from $350 at Wells Fargo - TipRanks
Truist Raises Price Target on Insulet to $390 From $365, Keeps Buy Rating - MarketScreener
Wolfe Research Adjusts Price Target on Insulet to $375 From $350, Maintains Outperform Rating - MarketScreener
Leerink Partners Adjusts Price Target on Insulet to $385 From $355, Maintains Outperform Rating - MarketScreener
Goldman Sachs Adjusts Price Target on Insulet to $388 From $375, Maintains Buy Rating - MarketScreener
Rothschild & Co Redburn Adjusts Price Target on Insulet to $380 From $370, Maintains Buy Rating - MarketScreener
Jefferies Maintains Insulet (PODD) Buy Recommendation - Nasdaq
Insulet price target raised to $316 from $301 at Barclays - TipRanks
Jefferies Adjusts Price Target on Insulet to $400 From $375, Maintains Buy Rating - MarketScreener
Canaccord Genuity Adjusts Price Target on Insulet to $428 From $399, Maintains Buy Rating - MarketScreener
Wells Fargo Adjusts Price Target on Insulet to $360 From $350, Maintains Overweight Rating - MarketScreener
Chart based exit strategy for Insulet CorporationJuly 2025 Summary & Comprehensive Market Scan Reports - newser.com
How institutional ownership impacts Insulet Corporation stockJuly 2025 Price Swings & Advanced Technical Analysis Signals - newser.com
How Insulet’s (PODD) Raised Outlook and Surging Omnipod Demand Will Impact Investors - simplywall.st
Insulet Q3 2025 slides: revenue surges 30%, guidance raised amid international expansion - Investing.com Nigeria
Insulet’s (NASDAQ:PODD) Q3: Strong Sales - The Globe and Mail
Insulet Corporation Reports Strong Q3 2025 Results - TipRanks
Insulet (PODD) Reports Q3 Earnings: What Key Metrics Have to Say - sharewise.com
Insulet (PODD) Q3 Earnings and Revenues Beat Estimates - sharewise.com
Earnings call transcript: Insulet beats Q3 2025 forecasts, stock rises By Investing.com - Investing.com Nigeria
Insulet raises full-year Omnipod revenue growth guidance to 29–30% as international momentum accelerates - MSN
Insulet Corp. Reveals Advance In Q3 Income - Nasdaq
Insulet Corporation Stock (PODD) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.21%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):